Squarepoint
PACB icon

Squarepoint’s Pacific Biosciences PACB Stock Holding History

Squarepoint’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,900
Closed -$25.5K – 4716
2025
Q3 		$25.5K Hold
19,900
– – ﹤0.01% 4276
2025
Q2 		$24.7K Sell
19,900
-400
-2% -$462 ﹤0.01% 4375
2025
Q1 		$24K Sell
20,300
-12,700
-38% -$19.5K ﹤0.01% 4425
2024
Q4 		$60.4K Buy
+33,000
New +$64.4K ﹤0.01% 4808

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Squarepoint's PACB Position: Q1 2026 in Review

Squarepoint sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 448,558 shares — an estimated $839K sold.

Squarepoint first reported a position in PACB in Q4 2014 and held it in 28 quarters. The position peaked at $9.62M in Q3 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Squarepoint reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 448,558 Pacific Biosciences shares in Q1 2026, an estimated $839K.
  • Squarepoint first reported a position in Pacific Biosciences in Q4 2014 and held it in 28 quarters.
  • Squarepoint's Pacific Biosciences position peaked at $9.62M in Q3 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.